Stay up to date on the latest Foundation news and research.

Join Today!
  • Skip to main content
  • Skip to footer
Foundation Fighting Blindness homepage
Search
My Chapter:
View Chapter
Donate
  • Understanding Vision Loss
    • Vision Loss Glossary
    • Retinal Education Videos
    • Achromatopsia
    • Bardet-Biedl Syndrome (BBS)
    • Best Disease
    • Choroideremia
    • CRB1-Associated Diseases
    • Geographic Atrophy (GA)
    • Leber Congenital Amaurosis (LCA)
    • Macular Degeneration
    • PRPH2-Associated Diseases
    • Retinitis Pigmentosa
    • Refsum Disease
    • Stargardt Disease
    • Thyroid Eye Disease
    • Usher Syndrome
    • X-Linked Retinoschisis (XLRS)
    • Rare Retinal Conditions
  • Living With Vision Loss
    • Information for the Newly Diagnosed
    • Mental Health Resource Center
    • Beacon Stories
    • Low Vision Resources
    • Retinal Doctors Directory
    • Accessibility Guidelines and Virtual Meeting Tips
  • Research
    • Science Strategic Plan
    • My Retina Tracker Program
    • Clinical Trials
    • Clinical Trial Pipeline
    • Grants &
Awards
    • Funded Projects
    • Eye Donor Program
    • Continuing Education
  • Get Involved
    • Join a Chapter
    • Register for VisionWalk
    • Donate Today
    • Host a Fundraiser
    • Legacy Giving
    • Shop to Support
    • Partner with Us
  • News
    • News
    • Foundation News
    • Podcasts
    • Find Foundation Podcasts
    • Music to Our Eyes Videos
    • In Focus Newsletter
    • Legacy Newsletter
    • For Media
    • RSS Feeds
    • Sign Up for Alerts
  • Events
    • Upcoming Events
    • VisionWalk
    • Insights Forum
    • VISIONS Conference
    • Awareness Calendar
  • Genetic Testing Program
  • For Eye Care Professionals
  • About
    • Mission & History
    • Board of Directors
    • Leadership
    • Strategic Council
    • Scientific Advisory Board
    • National Trustees
    • Corporate Partners
    • Financials & Governance
    • Annual Reports
    • Careers
    • Contact
  • Ways to Give
    • Credit Card, ACH & PayPal
    • Legacy Giving
    • Donor Advised Funds
    • Stock Donations
    • Crypto Donations
    • Join a VisionWalk
    • Host a Fundraiser
    • Corporate Partnerships
Change colorTheme

Science Strategic Plan

  • Email
  • Share on Facebook
  • X Tweet
  • Science Strategic Plan
  • FY25–FY29 Budget Allocation
  • Comprehensive Research Portfolio
  • Collaborations
  • Community Education

Introduction

For over 50 years, the Foundation Fighting Blindness has remained steadfast in pursuing its urgent mission of driving the research that will provide preventions, treatments, and cures for individuals affected by retinitis pigmentosa, Usher syndrome, Stargardt disease, Leber congenital amaurosis, age-related macular degeneration, and more. There are three pillars that underpin our mission and guide our work:

  • Comprehensive Research Portfolio of grants and awards.
  • Collaboration with partners to enhance and/or accelerate our goals.
  • Community Education to drive greater awareness and understanding of mission-related priorities for all internal and external stakeholders.

These focus areas have remained the same throughout the Foundation's history. Every five years, we take a closer look at these areas to find important opportunities that align with current advancements in the field. By focusing on the most promising areas, we can make progress that stays true to our mission. These opportunities help guide our funding decisions and key programs, ensuring we continue to push for new treatments for people affected by inherited retinal diseases (IRDs) and dry age-related macular degeneration (AMD).

Purpose

The fiscal year 2025–2029 Science Strategic Plan is developed with a single, overarching goal:

To drive research projects and activities to overcome barriers to translating preclinical research into clinical trials for individuals affected by inherited retinal diseases and dry AMD.

Upon completing this strategic plan, we will measure progress toward addressing barriers for translating our funded research to effective treatments for patients with IRDs and dry AMD. Our milestones include establishing validated clinical endpoints, funding restorative therapy research projects, creating innovative disease models, publishing regulatory guidance, advancing genetic insights, nurturing talent, fostering strategic collaborations, and promoting awareness.

Desired Outcomes

Upon completion of this strategic plan, we will have made significant strides toward developing effective treatments for patients with IRDs and dry AMD.

Our progress will be marked by:

  1. The establishment of three validated outcome measures to serve as reliable benchmarks in clinical trials, enhancing the relevance and clinical implications of our results.
  2. The cultivation and funding of three restorative therapy research projects with different approaches specifically targeting late-stage disease, broadening our understanding and approach to treating individuals at this disease stage.
  3. The creation of six innovative disease models for IRDs and dry AMD to propel potential treatments from the research phase to the clinic, accelerating the path to patient care.
  4. The publication of guidance for implementing immune mitigation protocols related to retinal diseases during disease progression and as a result of therapeutic interventions.
  5. The funding of research to understand the pathology and mechanism of disease for as many IRD genes as feasible.
  6. The release of an updated, commercially available IRD gene testing panel, offering the most current and comprehensive
    genetic insights for diagnosis and treatment planning.
  7. Talent recruitment and development of the next generation of research scientists focused on IRDs.
  8. Strategic collaborations to further the work of this strategic plan.
  9. Broad awareness and education of our work, both externally and internally, emphasizing the science initiatives within this strategic plan.

Each of these milestones represents a significant step forward in our mission to overcome barriers for translating research to treatments for IRDs and dry AMD.

chevron-thin-up scroll to top
Foundation Fighting Blindness homepage

The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon for those affected by these blinding diseases. Join the fight and help us accelerate our mission.

NORD 2025 Platinum Member Charity Watch Top Rated GuideStar 2020 Platinum Seal of Transparency GuideStar 2020 Platinum Seal of Transparency Better Business Bureau Accredited Charity Charity Navigator WCAG 2.1 compliant, level double A

The Foundation Fighting Blindness meets all 20 Better Business Bureau Charity Standards.

Stay connected by receiving updates and communications from the Foundation!

Sign Up

Get in Touch

  • Facebook.
  • Twitter. X
  • YouTube.
  • Instagram.
  • Linkedin. linkedin
  • Tiktok. tiktok

Foundation Fighting Blindness

Phone: (800) 683-5555

6925 Oakland Mills Road, #701, Columbia, MD 21045.

Donations can be mailed directly to:
Foundation Fighting Blindness, P.O. Box 45740, Baltimore, MD 21297-5740

  • Contact
  • Careers
  • For Media
  • Accessibility
  • Privacy Policy
  • Site Map

© 2025 Foundation Fighting Blindness, All Rights Reserved. The Foundation Fighting Blindness is a qualified 501(c)(3) non-profit organization and all donations are tax deductible. EIN 23-7135845.